155 related articles for article (PubMed ID: 27575630)
1. Prognostic Significance of Transitional Cell Carcinoma-Like Morphology of High-Grade Serous Ovarian Carcinoma: A Comparative Study.
Nasioudis D; Sisti G; Kanninen TT; Fambrini M; Di Tommaso M
Int J Gynecol Cancer; 2016 Nov; 26(9):1624-1629. PubMed ID: 27575630
[TBL] [Abstract][Full Text] [Related]
2. Transitional cell-like morphology in ovarian endometrioid carcinoma: morphologic, immunohistochemical, and behavioral features distinguishing it from high-grade serous carcinoma.
Karnezis AN; Aysal A; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2013 Jan; 37(1):24-37. PubMed ID: 23108017
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer.
Paik ES; Kim JH; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
J Gynecol Oncol; 2018 Jan; 29(1):e13. PubMed ID: 29185271
[TBL] [Abstract][Full Text] [Related]
4. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.
Ayhan A; Ozkan NT; Sarı ME; Celik H; Dede M; Akbayır Ö; Güngördük K; Şahin H; Haberal A; Güngör T; Arvas M; Meydanlı MM
J Gynecol Oncol; 2018 Jan; 29(1):e12. PubMed ID: 29185270
[TBL] [Abstract][Full Text] [Related]
5. Early stage primary ovarian mucinous carcinoma: Outcome-based clinicopathological study in comparison with serous carcinoma.
Tian Q; Lu B; Ye J; Lu W; Xie X; Wang X
J Int Med Res; 2016 Apr; 44(2):357-66. PubMed ID: 26880793
[TBL] [Abstract][Full Text] [Related]
6. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
7. Development and identification of a prognostic nomogram model for patients with mixed cell adenocarcinoma of the ovary.
Wu H; Jiang S; Zhong P; Li W; Zhang S
J Ovarian Res; 2021 Oct; 14(1):137. PubMed ID: 34674727
[TBL] [Abstract][Full Text] [Related]
8. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.
Cui X; Li L; Yan G; Meng K; Lin Z; Nan Y; Jin G; Li C
BMC Cancer; 2015 Apr; 15():244. PubMed ID: 25885439
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of nuclear morphometric analysis in serous ovarian carcinoma.
Palmer JE; Sant Cassia LJ; Irwin CJ; Morris AG; Rollason TP
Int J Gynecol Cancer; 2008; 18(4):692-701. PubMed ID: 17944918
[TBL] [Abstract][Full Text] [Related]
10. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis.
Rauh-Hain JA; Diver EJ; Clemmer JT; Bradford LS; Clark RM; Growdon WB; Goodman AK; Boruta DM; Schorge JO; del Carmen MG
Gynecol Oncol; 2013 Oct; 131(1):46-51. PubMed ID: 23906658
[TBL] [Abstract][Full Text] [Related]
11. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
[TBL] [Abstract][Full Text] [Related]
12. Malignant and borderline epithelial ovarian tumors in the pediatric and adolescent population.
Nasioudis D; Alevizakos M; Holcomb K; Witkin SS
Maturitas; 2017 Feb; 96():45-50. PubMed ID: 28041594
[TBL] [Abstract][Full Text] [Related]
13. Survival in women with grade 1 serous ovarian carcinoma.
Nickles Fader A; Java J; Ueda S; Bristow RE; Armstrong DK; Bookman MA; Gershenson DM;
Obstet Gynecol; 2013 Aug; 122(2 Pt 1):225-232. PubMed ID: 23969788
[TBL] [Abstract][Full Text] [Related]
14. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic characteristics and survival outcomes in neuroendocrine carcinoma of the ovary.
Zhu Y; Meng F; Fang H; Zhang Z; Wang L; Zheng W
Int J Gynecol Cancer; 2020 Feb; 30(2):207-212. PubMed ID: 31796530
[TBL] [Abstract][Full Text] [Related]
16. Prognosis comparison between small cell carcinoma of ovary and high-grade serous ovarian cancer: A retrospective observational cohort study.
Hu D; Ma D; Zhang ZJ; Zhang Y; Huang K; Li X
Front Endocrinol (Lausanne); 2023; 14():1103429. PubMed ID: 36742399
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of low-grade serous ovarian cancer.
Plaxe SC
Am J Obstet Gynecol; 2008 Apr; 198(4):459.e1-8; discussion 459.e8-9. PubMed ID: 18395040
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study.
Zhou J; He ZY; Li FY; Sun JY; Lin HX; Wu SG; Chen QH
Oncotarget; 2016 Feb; 7(7):7952-9. PubMed ID: 26788911
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma.
Lee M; Nam EJ; Kim SW; Kim S; Kim JH; Kim YT
Int J Gynecol Cancer; 2012 Nov; 22(9):1489-96. PubMed ID: 23095773
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.
Dao F; Schlappe BA; Tseng J; Lester J; Nick AM; Lutgendorf SK; McMeekin S; Coleman RL; Moore KN; Karlan BY; Sood AK; Levine DA
Gynecol Oncol; 2016 May; 141(2):260-263. PubMed ID: 26968641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]